Illumina, Veritas Launch Consortium Embedding Whole-Genome Sequencing into Health Insurance Plans
Illumina partnered with Veritas Genetics Powered by Fuze to form a consortium integrating population-scale whole-genome sequencing into U.S. health insurance plans and global markets. The opt-in preventive genomics program delivers early risk detection for hereditary cancer, cardiometabolic disease and medication response through streamlined sample collection, genetic counseling and actionable insights.
1. Consortium Formation
On March 16, Illumina and Veritas Genetics Powered by Fuze launched a strategic consortium that combines Illumina’s whole-genome sequencing and DRAGEN analysis pipelines with Veritas’ myGenome reporting, clinical interpretation and genetic counseling services.
2. Program Offerings
The initiative features an opt-in preventive genomics program offering clinical-grade whole-genome sequencing, streamlined sample collection, clear education and consent processes, member-ready reporting and access to genetic counseling with guideline-aligned care pathways.
3. Implementation and Reach
Targeting U.S. health insurance plans and additional global markets, the consortium aims to enable earlier identification of elevated risk for hereditary cancer, cardiometabolic disease and medication response at a population scale.
4. Strategic Significance
By creating a consented, integrated clinical-genomics dataset, the collaboration will support precision medicine research, drug discovery and clinical trial optimization, aligning with Illumina’s goal to expand evidence-based adoption of genomics in proactive healthcare.